Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04152018 · ClinicalTrials.gov registry record · Phase 1
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04152018 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 85 participants.
The verdict
NCT04152018, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 3 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.
Interventions
- DRUG PF-06801591
- DRUG PF-06940434
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2024-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04152018
The ClinicalTrials.gov registry entry for NCT04152018 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06801591 is the first listed.
NCT04152018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04152018 about?
NCT04152018 is a clinical study titled "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.". Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clea...
What is the current status of trial NCT04152018?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2019-11-13. Estimated completion is 2024-12-10.
What interventions are being tested in trial NCT04152018?
The interventions under investigation include: PF-06801591 (DRUG), PF-06940434 (DRUG).
Who is sponsoring clinical trial NCT04152018?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.